- 2023 Multidisciplinary Oncology Review
- 2022
- Videos
- 2021
- 2020
- 2019
- Hematology & Medical Oncology Review 2019
- 2018
- Events
Playback speed
10 seconds
KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ibrutinib + Rituximab vs. FCR
386 views
October 4, 2019
Comments 0
Login to view comments.
Click here to Login
Hematologic Malignancies